Back to article: LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

FIGURE 2: LTX-315's initial phase of antitumor response is defined by rapid disruption of the tumor vasculature and occurs independently of lymphocytes. (A) Schematic of B16F10 melanoma experiments: Rag2–/– or control wild type (WT) mice bearing B16F10 melanoma tumor grafts were either treated intratumorally (i.t.) with LTX-315 or left untreated. (B) B16F10 tumor volumes immediately before (d0) and four days after LTX-315 treatment (d4) in individual WT mice (dark blue) and Rag2–/– mice (light blue). Untreated Rag2–/– mice (grey) were used as controls; n = 4 mice/group. (C) Cumulative B16F10 tumor volumes over time of mice treated as in (B). (D) Intravital microscopy of a vasculature agent (Dextran-VT680, white) at different time points before and after intratumoral LTX-315 injection in mice bearing B16F10-GFP melanoma tumors (green). (E) Intravital microscopy of two vasculature agents (Dextran-VT680, white; Dextran-TRITC, red) in mice bearing two B16F10-GFP melanoma tumors (Tumors A and B) and after intratumoral LTX-315 injection in Tumor A only. Dextran-VT680 was injected 10 min before LTX-315 administration, whereas Dextran-TRITC was given 60 min later. Abbreviations are as follows: d = day.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.